Last reviewed · How we verify

Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients (DEXsedation)

NCT02606409 Phase 2/Phase 3 COMPLETED

Dexmedetomidine, a central and peripheral α2-receptor agonist distinct from GABA receptor for benzodiazepines and propofol, has been approved by the US Food and Drug Administration only for use up to 24 h in mechanically ventilated patients. The investigators aim to compare dexmedetomidine with propofol for sedation \>24h in poly traumatized mechanically ventilated patients.

Details

Lead sponsorAssiut University
PhasePhase 2/Phase 3
StatusCOMPLETED
Enrolment60
Start date2015-11
Completion2016-06

Conditions

Interventions

Primary outcomes

Countries

Egypt